Economic Rules Hub
  • World
  • Politics
  • Business
  • Investing
Home Business Biden administration to lower costs for 64 drugs through inflation penalties on drugmakers
Business

Biden administration to lower costs for 64 drugs through inflation penalties on drugmakers

by admin June 29, 2024
June 29, 2024

The Biden administration on Wednesday said it will impose inflation penalties on 64 prescription drugs for the third quarter of this year, lowering costs for certain older Americans enrolled in Medicare. 

President Joe Biden has made lowering U.S. drug prices a key pillar of his health-care agenda and reelection platform for 2024. A provision of Biden’s Inflation Reduction Act requires drugmakers to pay rebates to Medicare, the federal health program for Americans over age 65, if they hike the price of a medication faster than the rate of inflation. 

It is separate from another provision under the law that allows Medicare to negotiate lower prescription drug prices with manufacturers. On average, Americans pay two to three times more than patients in other developed nations for prescription drugs, according to the Biden administration.

Some patients will pay a lower coinsurance rate for the 64 drugs covered under Wednesday’s announcement, which fall under Medicare Part B, for the period from July 1 to Sept. 30 “since each drug company raised prices faster than the rate of inflation,” according to a release from the administration.

Some Medicare Part B patients may save as much as $4,593 per day if they use those drugs during the quarter, the release added.  

More than 750,000 Medicare patients use the drugs each year, according to the release. The medications treat conditions such as cancer, certain infections and a bone disease called osteoporosis.

“Without the Inflation Reduction Act, seniors were completely exposed to Big Pharma’s price hikes. Not anymore,” Neera Tanden, White House domestic policy advisor, said in the release.

The Centers for Medicare & Medicaid Services plans to send the first invoices to drugmakers in 2025 for the rebates owed to the program.

In December, Biden released a list of 48 prescription drugs that would be subject to inflation penalties during the first quarter of 2024.

This post appeared first on NBC NEWS

0
FacebookTwitterPinterestEmail
previous post
France is set for its most consequential election in decades. Here’s what you need to know
next post
YouTube is dominating the living room, forcing media companies to decide whether it’s friend or foe

Related Posts

Starbucks moves to the next phase in its turnaround: Winning...

June 17, 2025

Trump made millions on guitars, Bibles and watches with his...

June 17, 2025

Anne Wojcicki to buy back 23andMe and its data for...

June 16, 2025

Trump says national security concerns in Nippon-U.S. Steel deal can...

June 15, 2025

Howard Schultz says he ‘did a cartwheel’ when Starbucks CEO...

June 13, 2025

U.S. online stores put up ‘out of stock’ signs as...

June 12, 2025

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent

    • Netanyahu says Israel’s operation may lead to regime change in Iran. How likely is that?

      June 17, 2025
    • ‘Like the world has forgotten us:’ As Iran-Israel conflict escalates, Gazans fear their suffering will become invisible

      June 17, 2025
    • Iran’s Mossad paranoia grows, amid fears of Israeli spies wearing ‘masks, hats and sunglasses’

      June 17, 2025
    • 14 killed in worst Russian strikes on Kyiv in weeks

      June 17, 2025
    • Built inside a mountain and hardened against bunker-busting bombs. Here’s what we know about Iran’s Fordow nuclear site

      June 17, 2025

    Categories

    • Business (1,406)
    • Investing (3,462)
    • Politics (4,640)
    • World (4,538)
    • Email Whitelisting
    • Terms and Conditions
    • Privacy Policy
    • Contacts
    • About us

    Disclaimer: EconomicRulesHub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 EconomicRulesHub.com | All Rights Reserved

    Economic Rules Hub
    • World
    • Politics
    • Business
    • Investing